Hologic (NSDQ:HOLX) announced today that it completed regulatory steps allowing it to make Panther Trax available across a number of geographies.
Marlborough, Massachusetts-based Hologic’s launch of Panther Trax offers a new addition to its Panther scalable solutions (PSS) portfolio of products, enhancing lab automation through the physical linking of multiple Panther instruments into a single workcell that allows for an increase in testing volumes without increasing staff.
According to a news release, Panther Trax holds the listing of a Class I medical device with the FDA and has CE mark approval in Europe. It will also be available commercially in Canada, Australia and New Zealand, Hologic said.
Panther Trax offers full automation to meet high-volume testing demands, allowing labs to customize configuration to meet space constraints and minimize facility costs.
“Clinical laboratories have performed heroically, meeting unprecedented demand for close to two years now due to the COVID-19 pandemic,” Hologic President of Diagnostic Solutions Kevin Thornal said in the release. “It is the job of manufacturers like Hologic to continue to innovate and enable our lab partners to accomplish more with less, ensuring they manage their workloads while responding to further potential surges in COVID testing.”